Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry

ALEJANDRO ESCUDERO CONTRERASALEJANDRO ESCUDERO CONTRERASEDUARDO COLLANTES ESTÉVEZPILAR FONT UGALDE2026-01-292026-01-29201610.1007/s00296-015-3374-22-s2.0-84955360138https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/26737ImmunologyImmunology and AllergyRheumatologyReal-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registryresearch article